Chang, T I
Abdalla, S
London, G M
Block, G A
Correa-Rotter, R
Drüeke, T B
Floege, J
Herzog, C A
Mahaffey, K W
Moe, S M
Parfrey, P S
Wheeler, D C
Dehmel, B
Goodman, W G
Chertow, G M
Article History
Received: 24 November 2014
Revised: 9 April 2015
Accepted: 29 April 2015
First Online: 4 June 2015
Competing interests
: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Grant, consulting fee/honorarium, speaking fees, stock options or travel support relevant to current manuscript: Abbott/Abbvie: JF, CH, RC-R, DW; Affymax: CH; Amgen: SA, GB, GC, TD, JF, CH, GL, SM, PP, RC-R, DW (note: no honoraria were received for writing or reviewing the manuscript); Astra Zeneca: RC-R; Chugai Pharmaceutical Co: JF; ClearView Healthcare Partners: CH; CorMedix: CH; Danone: RC-R; Davita: GB; Eli Lilly: SM; Fibrogen: CH; Fresenius Medical Care: TD, JF, RC-R, DW; Genzyme/Sanofi: GB, TD, JF, SM, RC-R, DW; Johnson & Johnson: CH, RC-R; KAI Pharmaceuticals: GB, SM; Keryx: GB, GC, CH; Medtronic: CH; Merck: DW, CH; Novartis: SM; Otsuka: DW; Pfizer: RC-R; Reata Pharmaceuticals: RC-R; Roche: RC-R; Satellite Healthcare: GC; Shire: JF, SM, DW; Vifor: JF, SM, DW; ZS Pharma: CH, DW. Employees and stock holders of Amgen: BD, WG. KM’s financial disclosures before 1 August 2013, can be viewed at ExternalRef removed; disclosures after 1 August 2013, can be viewed at ExternalRef removed.